# China NMPA Drug Inspection - Wanbangde Pharmaceutical Group Co., Ltd. - Ginkgo Leaf Droplets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/wanbangde-pharmaceutical-group-co-ltd/9370b54e-4185-4599-b91b-f154ffb10aa6/
Source feed: China

> China NMPA drug inspection for Wanbangde Pharmaceutical Group Co., Ltd. published October 15, 2015. Drug: Ginkgo Leaf Droplets. The State Food and Drug Administration (SFDA) published an announcement on October 15, 2015, detailing the results of ma

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 73 of 2015 from the State Food and Drug Administration on the Results of Spot Checks on Ginkgo Leaf Soft Capsules and Other Ginkgo Leaf Drugs
- Company Name: Wanbangde Pharmaceutical Group Co., Ltd.
- Publication Date: 2015-10-15
- Drug Name: Ginkgo Leaf Droplets
- Inspection Finding: Product failed inspection.
- Action Taken: They have been ordered to immediately recall all substandard products already on the market and will be investigated and prosecuted according to law.
- Summary: The State Food and Drug Administration (SFDA) published an announcement on October 15, 2015, detailing the results of market sampling inspections for Ginkgo Leaf drug products. The China National Institutes for Food and Drug Control conducted these inspections, guided by supplementary methods established under SFDA Announcement No. 142 of 2015. A total of 168 product batches were analyzed, revealing 16 batches of Ginkgo Leaf Soft Capsules and 13 batches of Ginkgo Leaf Drop Pills to be substandard. The companies identified for producing these substandard products include Liaoning Shengsheng Pharmaceutical Group Co., Ltd. Pharmaceutical Branch, Liaoning Xiancaotang Pharmaceutical Co., Ltd., and Luoyang Junshan Pharmaceutical Co., Ltd. for soft capsules, and Wanbangde Pharmaceutical Group Co., Ltd. for drop pills. Liaoning Shengsheng and Liaoning Xiancaotang had already initiated voluntary product recalls. Conversely, Luoyang Junshan and Wanbangde were directed to immediately recall all substandard products from the market, with a deadline of October 20, 2015. Regulatory authorities in Liaoning, Henan, and Zhejiang Provinces were tasked with supervising these recalls, publicly disclosing information, and pursuing legal enforcement against the implicated companies, with reports due to the SFDA by October 22, 2015. Additionally, drug distribution and healthcare entities were mandated to discontinue the sale and use of the substandard products and report any findings. All relevant parties were required to conduct comprehensive recalls and issue full refunds to consumers, aligning with SFDA Notice [2015] No. 9.

Company: https://www.globalkeysolutions.net/companies/wanbangde-pharmaceutical-group-co-ltd/3142ca36-a8ae-4d59-b5aa-44701d273851/